From ec3b982cd54a53e88f3fbfd6a853b6d355354386 Mon Sep 17 00:00:00 2001 From: FMS Date: Wed, 5 Jun 2024 09:00:32 +0200 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Annual Meeting___2024___Notas.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/pages/STOP2030___Annual Meeting___2024___Notas.md b/pages/STOP2030___Annual Meeting___2024___Notas.md index f6feb133..83c2cb83 100644 --- a/pages/STOP2030___Annual Meeting___2024___Notas.md +++ b/pages/STOP2030___Annual Meeting___2024___Notas.md @@ -9,4 +9,4 @@ - [[Mwandawiro]]: In the room we have colleagues from Ghana. People from different countries but in Africa we have Ghana and Kenya. We started the journey of STOP in 2018. We had colleages from Ethiopia and Mozambique. Ghana give me some nostalgic memories because in 2002, 2003 we started deworming activities with JICA. They came and stablished ESASIPAC. In Ghana they established WASASIPAC (for the West). We in Kenya and our colleagues in Ghana we're visiting each other and comparing notes. And we're here again in a consortium that joins us together. Please that the team from Ghana includes a prominent researcher, Abraham Oduro. - [[Abraham Oduro]]: Director of Research for GHS. WP2. Dr Opare is the program manager for NTDs. We implement all the policies of the ministry. When I speak I do it for the director general. Division for R&D. We have the needed support to succeed. I wish everybody well and we're here to contribute positively. - [[Joseph Opare]]: we're privileged to be part of this consortium. We continue to have this infection. We've treated this condition for more than 15 years. Multifaceted approach. Happy to be part of this consortium. -- PPB: She's not a director. The previous speakers have spoken. I have the written speach from the director. National drug regulatory authority. We're involved in RCT were we try to get the input of the scientists. One of our mandates is to have products with quality, efficacious and safe. When it is needed, it has to be available. When a product is licensed by the PPB. Ghana people, we privileged to have you. We're in touch with the Ghana FDA, we have counterparts. We can consult with them. For a long time alb and mlb. The need for repeated dosing. The one health guideline development group recomended further research in alternative antihelminthic medication or combination \ No newline at end of file +- PPB: She's not a director. The previous speakers have spoken. I have the written speach from the director. National drug regulatory authority. We're involved in RCT were we try to get the input of the scientists. One of our mandates is to have products with quality, efficacious and safe. When it is needed, it has to be available. When a product is licensed by the PPB. Ghana people, we privileged to have you. We're in touch with the Ghana FDA, we have counterparts. We can consult with them. For a long time alb and mlb. The need for repeated dosing. The one health guideline development group recomended further research in alternative antihelminthic medication or combination to avoid resistance development. The prooposed fdc of alb/ivm represents a promising advancement for those ailed by this disease. the ppb is commited to: 1: ensure that all mediciens approved \ No newline at end of file